ExCellThera rencontrera les investisseurs durant la 42e conférence annuelle J.P. Morgan Healthcare et participera aux prochaines conférences d'investisseurs
January 02, 2024 07:00 ET
|
ExCellThera
MONTREAL, 02 janv. 2024 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), un leader mondial des thérapies à base de cellules souches sanguines amplifiées, a annoncé aujourd'hui que ses hauts...
ExCellThera to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference and to Participate in Upcoming Investor Conferences
January 02, 2024 07:00 ET
|
ExCellThera
ExCellThera senior leaders will be holding investor meetings during JP Morgan Heathcare Conference and participating in upcoming investor conferences.
ExCellThera annonce les résultats positifs des études de phase 2 de la thérapie cellulaire UM171 chez des patients atteints de leucémies et de myélodysplasies à haut risque lors du congrès annuel 2023 de l'American Society of Hematology (ASH)
December 12, 2023 07:00 ET
|
ExCellThera
- Données présentées lors d'une séance orale à l'ASH 2023, s'appuyant sur des données solides antérieures issues d'une étude de phase 1/2 et d'études comparatives de registres. - La thérapie...
ExCellThera Announces Positive Phase 2 Study Results from UM171 Cell Therapy in Patients with High-risk Leukemias and Myelodysplasias at American Society of Hematology (ASH) 2023 Annual Meeting
December 12, 2023 07:00 ET
|
ExCellThera
50 patients evaluated in Phase 2 studies; ExCellThera’s UM171 showed excellent clinical outcomes for this high-risk leukemia/myelodysplasia cohort
ExCellThera announces new UM171 data to be presented at ASH 2023
November 03, 2023 08:15 ET
|
ExCellThera
ExCellThera announced today several UM171 presentations at ASH2023, including new data from Phase 2 studies in high-risk blood cancer patients
UM171 cell therapy demonstrates improved outcomes compared to cord and matched unrelated donor peripheral blood transplants in real-world setting
December 12, 2022 08:25 ET
|
ExCellThera
MONTRÉAL, Dec. 12, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today findings from a safety and efficacy...
ExCellThera announces completion of Phase 2 clinical trials for UM171-expanded cell therapy in high-risk blood cancers
November 15, 2022 08:32 ET
|
ExCellThera
MONTREAL, Nov. 15, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today the completion of patient enrollment in its...
ExCellThera announces 100th patient treated with UM171-expanded cell therapy
November 08, 2022 08:35 ET
|
ExCellThera
MONTREAL, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that its proprietary ECT-001 Cell Therapy...
ExCellThera announces oral presentation of new data on UM171-expanded cell therapy at the ASH Annual Meeting
November 04, 2022 09:30 ET
|
ExCellThera
MONTREAL, Nov. 04, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that an abstract related to ExCellThera’s...
ExCellThera announces submission of Drug Master File for UM171
June 17, 2022 08:05 ET
|
ExCellThera
MONTRÉAL, June 17, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), an advanced clinical-stage biotechnology company delivering molecules and bioengineering solutions to expand and...